# WNT7B drives a program for pancreatic cancer subtype switching and progression

**Authors:** Joep Sprangers, Jeroen M. Bugter, Despina Xanthakis, Michiel Boekhout, Rutger N.U. Kok, Veerle E. Geurts, Hans Clevers, Lodewijk A.A. Brosens, Frederike Dijk, Maria J. Rodríguez Colman, Jelte Y. van der Vaart, Madelon M. Maurice

PMC · DOI: 10.1016/j.isci.2026.115050 · 2026-02-17

## TL;DR

The WNT7B protein promotes aggressive pancreatic cancer by maintaining a specific cancer subtype and supporting tumor growth through cell contact.

## Contribution

This study reveals how WNT7B drives pancreatic cancer progression and subtype stability through direct cell-cell interactions.

## Key findings

- WNT7B sustains pancreatic cancer cell growth and survival by maintaining a basal-like subtype.
- WNT-high and WNT-low cells coexist as stable lineages within pancreatic tumors.
- WNT7B-expressing cells support neighboring cells via direct contact-dependent signaling.

## Abstract

Hyperactivation of WNT signaling is a hallmark of cancer, often driven by increased expression of WNT ligands. In pancreatic ductal adenocarcinoma (PDAC), elevated WNT7B and WNT10A correlate with aggressive, basal-like disease and poor patient survival, but the mechanisms underlying this association remain unclear. Using patient-derived organoids, we show that WNT7B promotes proliferation and maintains basal-like transcriptional states by preventing differentiation toward a more classical PDAC signature. Clonal WNT7B reporter organoids reveal that WNT-high cells are heterogeneously distributed and stably coexist with WNT-low/negative lineages. Hybrid co-cultures demonstrate that WNT7B-expressing cells support the survival and growth of neighboring WNT-negative cells via short-range, contact-dependent signaling. These findings highlight the functional importance of heterogeneous WNT7B/10A expression in driving PDAC aggressiveness and suggest that targeted WNT inhibition may shift tumors toward a more differentiated, less aggressive state, offering potential therapeutic benefit.

•Epithelial WNT7B and WNT10A sustain PDAC cell growth and survival•WNThigh and WNTlow cells coexist within PDAC as stable lineages•WNT7B shifts PDAC toward a basal-like state by suppressing the classical signature•WNThigh cells support neighboring WNTlow cells via direct cell-cell contact

Epithelial WNT7B and WNT10A sustain PDAC cell growth and survival

WNThigh and WNTlow cells coexist within PDAC as stable lineages

WNT7B shifts PDAC toward a basal-like state by suppressing the classical signature

WNThigh cells support neighboring WNTlow cells via direct cell-cell contact

Cell biology; Functional aspects of cell biology; Cancer

## Linked entities

- **Genes:** WNT7B (Wnt family member 7B) [NCBI Gene 7477], WNT10A (Wnt family member 10A) [NCBI Gene 80326]
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184)

## Full-text entities

- **Genes:** CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CES2 (carboxylesterase 2) [NCBI Gene 8824] {aka CE-2, CES2A1, PCE-2, iCE}, UCA1 (urothelial cancer associated 1) [NCBI Gene 652995] {aka CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36}, SMAD7 (SMAD family member 7) [NCBI Gene 4092] {aka CRCS3, MADH7, MADH8}, WNT5A (Wnt family member 5A) [NCBI Gene 7474] {aka hWNT5A}, H2BC21 (H2B clustered histone 21) [NCBI Gene 8349] {aka GL105, H2B, H2B-GL105, H2B.1, H2BE, H2BFQ}, CSF1R (colony stimulating factor 1 receptor) [NCBI Gene 1436] {aka BANDDOS, C-FMS, CD115, CSF-1R, CSFR, FIM2}, GLI2 (GLI family zinc finger 2) [NCBI Gene 2736] {aka CJS, HPE9, PHS2, THP1, THP2}, MUC5AC (mucin 5AC, oligomeric mucus/gel-forming) [NCBI Gene 4586] {aka MUC5, TBM, leB, mucin}, RNF43 (ring finger protein 43) [NCBI Gene 54894] {aka RNF124, SSPCS, URCC}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], LGR5 (leucine rich repeat containing G protein-coupled receptor 5) [NCBI Gene 8549] {aka FEX, GPR49, GPR67, GRP49, HG38}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, AXIN2 (axin 2) [NCBI Gene 8313] {aka AXIL, ODCRCS}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, PORCN (porcupine O-acyltransferase) [NCBI Gene 64840] {aka DHOF, FODH, MG61, PORC, PPN}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, WNT11 (Wnt family member 11) [NCBI Gene 7481] {aka HWNT11}, ZNRF3 (zinc and ring finger 3) [NCBI Gene 84133] {aka BK747E2.3, RNF203}, TFF1 (trefoil factor 1) [NCBI Gene 7031] {aka BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, AXIN1 (axin 1) [NCBI Gene 8312] {aka AXIN, CMDOH, PPP1R49}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, REG4 (regenerating family member 4) [NCBI Gene 83998] {aka GISP, REG-IV, RELP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, HNF1A (HNF1 homeobox A) [NCBI Gene 6927] {aka HNF-1-alpha, HNF-1A, HNF1, HNF1alpha, IDDM20, LFB1}, TP63 (tumor protein p63) [NCBI Gene 8626] {aka AIS, B(p51A), B(p51B), EEC3, KET, LMS}, TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, RPA2 (replication protein A2) [NCBI Gene 6118] {aka REPA2, RP-A p32, RP-A p34, RPA32}, Mucin [NCBI Gene 100508689], EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CAV2 (caveolin 2) [NCBI Gene 858] {aka CAV}, WNT2 (Wnt family member 2) [NCBI Gene 7472] {aka INT1L1, IRP}, Porcn (porcupine O-acyltransferase) [NCBI Gene 53627] {aka 2410004O13Rik, DXHXS7465e, Mg61, Mporc, Ppn, mMg61}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, ANXA10 (annexin A10) [NCBI Gene 11199] {aka ANX14}, MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, WNT7B (Wnt family member 7B) [NCBI Gene 7477], IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, POLA1 (DNA polymerase alpha 1, catalytic subunit) [NCBI Gene 5422] {aka NSX, PDR, POLA, VEODS, p180}, TFF2 (trefoil factor 2) [NCBI Gene 7032] {aka SML1, SP}, Wnt10a (wingless-type MMTV integration site family, member 10A) [NCBI Gene 22409], Wnt7b (wingless-type MMTV integration site family, member 7B) [NCBI Gene 22422] {aka Wnt-7b}, GATA6 (GATA binding protein 6) [NCBI Gene 2627], RSPO1 (R-spondin 1) [NCBI Gene 284654] {aka CRISTIN3, RSPO}, E2F4 (E2F transcription factor 4) [NCBI Gene 1874] {aka E2F-4}, WNT3A (Wnt family member 3A) [NCBI Gene 89780], WNT7A (Wnt family member 7A) [NCBI Gene 7476] {aka SANTOS, Wnt-7a}, Wnt3a (wingless-type MMTV integration site family, member 3A) [NCBI Gene 22416] {aka Wnt-3a, vt}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, TFF3 (trefoil factor 3) [NCBI Gene 7033] {aka ITF, P1B, TFI}, MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}
- **Diseases:** basal (MESH:D002280), esophageal cancer (MESH:D004938), hypersensitivity (MESH:D004342), like disease (MESH:C537675), toxicity (MESH:D064420), mucinous (MESH:D002288), Mortality (MESH:D003643), preneoplastic (MESH:D011230), colorectal cancer (MESH:D015179), metastasis (MESH:D009362), hypoxia (MESH:D000860), gastric metaplasia (MESH:D008679), CLS (MESH:D038921), gastric cancer (MESH:D013274), lung adenocarcinoma (MESH:D000077192), IPMNs (MESH:D000077779), pancreatic injury (MESH:D010195), epithelial tumor (MESH:D002277), MCNs (MESH:D018297), Cancer (MESH:D009369), bile duct cancer (MESH:D001650), PDAC cancer (MESH:D010190), PDAC (MESH:D021441), inflammation (MESH:D007249), prostate cancer (MESH:D011471)
- **Chemicals:** formalin (MESH:D005557), DMSO (MESH:D004121), DAPI (MESH:C007293), polyA (MESH:D011061), PBS (MESH:D007854), Tween-20 (MESH:D011136), N-acetylcysteine (MESH:D000111), Polybrene (MESH:D006583), Paraformaldehyde (MESH:C003043), SYBR green (MESH:C098022), A83-01 (MESH:C507011), 2-mercaptoethanol (MESH:D008623), Alexa568 (MESH:C000607448), Penicillin (MESH:D010406), puromycin (MESH:D011691), HEPES (MESH:D006531), Alexa-647 (MESH:C569686), Alexa FluorTM 568 (-), hydrogen peroxide (MESH:D006861), S (MESH:D013455), Y-27632 (MESH:C108830), GlutaMAX (MESH:C054122), cholesterol (MESH:D002784), SDS (MESH:D012967), LGK-974 (MESH:C586458), L (MESH:D007930), Nicotinamide (MESH:D009536), Hygromycin (MESH:C026273), Triton X-100 (MESH:D017830), Streptomycin (MESH:D013307), blasticidin (MESH:C004500), P/ (MESH:D010758), phosphate (MESH:D010710), Phalloidin (MESH:D010590), platinum (MESH:D010984), Zeocin (MESH:C105427), nylon (MESH:D009757), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606], Woodchuck hepatitis virus (no rank) [taxon 35269], Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** T2A, 2X
- **Cell lines:** W3A — Mus musculus (Mouse), Embryonic stem cell (CVCL_Y633), T-145 — Mus musculus (Mouse), Hybridoma (CVCL_XJ68), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), LCM — Panthera pardus (Leopard), Finite cell line (CVCL_A9GN), L — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0462)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12961301/full.md

---
Source: https://tomesphere.com/paper/PMC12961301